Priliximab

Drug Profile

Priliximab

Alternative Names: Anti-CD4 MAb; CEN 000029; Centara; cMT 412; MT 412

Latest Information Update: 01 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Centocor
  • Class Monoclonal antibodies
  • Mechanism of Action CD4 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Crohn's disease; Heart transplant rejection; Multiple sclerosis; Non-Hodgkin's lymphoma; Rheumatoid arthritis

Most Recent Events

  • 18 Oct 1999 Centocor is now a wholly owned subsidiary of Johnson & Johnson
  • 04 Aug 1999 No-Development-Reported for Multiple sclerosis in Sweden (IV)
  • 04 Aug 1999 No-Development-Reported for Multiple sclerosis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top